Ultragenyx Pharmaceutical Inc
RARE
查看详细走势图
24.110USD
-0.260-1.07%
收盘 01/13, 16:00（美东）报价延迟15分钟
2.33B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.07%
5天
+6.97%
1月
-33.45%
6月
-18.30%
今年开始到现在
+4.83%
1年
-44.14%
查看详细走势图
TradingKey Ultragenyx Pharmaceutical Inc股票评分
单位: USD 更新时间: 2026-01-13操作建议
Ultragenyx Pharmaceutical Inc当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在药品行业排名53/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价67.60。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Ultragenyx Pharmaceutical Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Ultragenyx Pharmaceutical Inc亮点
亮点风险
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
业绩高增长
公司营业收入稳步增长，连续3年增长54.19%
估值高估
公司最新PE估值-4.07，处于3年历史高位
机构减仓
最新机构持股100.03M股，环比减少2.53%
保罗·都铎·琼斯持仓
明星投资者保罗·都铎·琼斯持仓，最新持仓市值59.28K
活跃度降低
近期活跃度降低，过去20天平均换手率0.41
分析师目标
根据
21
位分析师
买入
评级
67.600
目标均价
+200.31%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Ultragenyx Pharmaceutical Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Ultragenyx Pharmaceutical Inc简介
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
公司代码RARE
公司Ultragenyx Pharmaceutical Inc
CEOKakkis (Emil D)
网址https://www.ultragenyx.com/
常见问题
Ultragenyx Pharmaceutical Inc(RARE)的当前股价是多少？
Ultragenyx Pharmaceutical Inc(RARE)的当前股价是 24.110。
Ultragenyx Pharmaceutical Inc的股票代码是什么？
Ultragenyx Pharmaceutical Inc的股票代码是RARE。
Ultragenyx Pharmaceutical Inc股票的52周最高点是多少？
Ultragenyx Pharmaceutical Inc股票的52周最高点是46.500。
Ultragenyx Pharmaceutical Inc股票的52周最低点是多少？
Ultragenyx Pharmaceutical Inc股票的52周最低点是18.410。
Ultragenyx Pharmaceutical Inc的市值是多少？
Ultragenyx Pharmaceutical Inc的市值是2.33B。
Ultragenyx Pharmaceutical Inc的净利润是多少？
Ultragenyx Pharmaceutical Inc的净利润为-569.18M。
现在Ultragenyx Pharmaceutical Inc(RARE)的股票是买入、持有还是卖出？
根据分析师评级，Ultragenyx Pharmaceutical Inc(RARE)的总体评级为买入，目标价格为67.600。
Ultragenyx Pharmaceutical Inc(RARE)股票的每股收益（EPS TTM）是多少
Ultragenyx Pharmaceutical Inc(RARE)股票的每股收益（EPS TTM）是-5.927。
相关品种
